产品描述
*The optimal dilutions should be determined by the end user.
*Tips:
WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.
展开/折叠
Enhancer of zeste 2; enhancer of zeste 2 polycomb repressive complex 2 subunit; Enhancer of zeste homolog 2 (Drosophila); Enhancer of zeste homolog 2; Enhancer of zeste, Drosophila, homolog 2; ENX 1; Enx 1h; ENX-1; ENX1; Enx1h; EZH 2; EZH1; EZH2; EZH2_HUMAN; EZH2b; Histone-lysine N-methyltransferase EZH2; KMT 6; KMT6; KMT6A; Lysine N-methyltransferase 6; MGC9169; WVS; WVS2;
抗原和靶标
Expressed in many tissues. Overexpressed in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma and testis.
- Q15910 EZH2_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MGQTGKKSEKGPVCWRKRVKSEYMRLRQLKRFRRADEVKSMFSSNRQKILERTEILNQEWKQRRIQPVHILTSVSSLRGTRECSVTSDLDFPTQVIPLKTLNAVASVPIMYSWSPLQQNFMVEDETVLHNIPYMGDEVLDQDGTFIEELIKNYDGKVHGDRECGFINDEIFVELVNALGQYNDDDDDDDGDDPEEREEKQKDLEDHRDDKESRPPRKFPSDKIFEAISSMFPDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLHPFHATPNTYKRKNTETALDNKPCGPQCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPSTPTINVLESKDTDSDREAGTETGGENNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAEASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIIAPAPAEDVDTPPRKKKRKHRLWAAHCRKIQLKKDGSSNHVYNYQPCDHPRQPCDSSCPCVIAQNFCEKFCQCSSECQNRFPGCRCKAQCNTKQCPCYLAVRECDPDLCLTCGAADHWDSKNVSCKNCSIQRGSKKHLLLAPSDVAGWGIFIKDPVQKNEFISEYCGEIISQDEADRRGKVYDKYMCSFLFNLNNDFVVDATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAIQTGEELFFDYRYSQADALKYVGIEREMEIP
翻译修饰 - Q15910 作为底物
Site | PTM Type | Enzyme | Source |
---|---|---|---|
K7 | Ubiquitination | Uniprot | |
S8 | Phosphorylation | Uniprot | |
K10 | Ubiquitination | Uniprot | |
S21 | Phosphorylation | P31749 (AKT1) | Uniprot |
Y23 | Phosphorylation | Uniprot | |
K39 | Ubiquitination | Uniprot | |
K61 | Ubiquitination | Uniprot | |
S75 | O-Glycosylation | Uniprot | |
S76 | O-Glycosylation | Uniprot | |
S76 | Phosphorylation | Uniprot | |
S212 | Phosphorylation | Uniprot | |
S220 | Phosphorylation | Uniprot | |
K234 | Acetylation | Uniprot | |
K234 | Ubiquitination | Uniprot | |
Y244 | Phosphorylation | Uniprot | |
T261 | Phosphorylation | Uniprot | |
S277 | Phosphorylation | Uniprot | |
T302 | Phosphorylation | Uniprot | |
T305 | Phosphorylation | Uniprot | |
T311 | Phosphorylation | Uniprot | |
K318 | Ubiquitination | Uniprot | |
T339 | Phosphorylation | Uniprot | |
T345 | Phosphorylation | P24941 (CDK2) , P06493 (CDK1) | Uniprot |
K348 | Acetylation | Uniprot | |
S362 | Phosphorylation | Uniprot | |
S363 | Phosphorylation | P49841 (GSK3B) | Uniprot |
S366 | Phosphorylation | Uniprot | |
T367 | Phosphorylation | P49841 (GSK3B) , Q16539 (MAPK14) | Uniprot |
T369 | Phosphorylation | Uniprot | |
S375 | Phosphorylation | Uniprot | |
S380 | Phosphorylation | Uniprot | |
T388 | Phosphorylation | Uniprot | |
S405 | Phosphorylation | Uniprot | |
S406 | Phosphorylation | Uniprot | |
S408 | Phosphorylation | Uniprot | |
S412 | Phosphorylation | Uniprot | |
T416 | Phosphorylation | P24941 (CDK2) | Uniprot |
T460 | Phosphorylation | Uniprot | |
K461 | Ubiquitination | Uniprot | |
K472 | Ubiquitination | Uniprot | |
S474 | Phosphorylation | Calculation | |
S475 | Phosphorylation | Calculation | |
T487 | Phosphorylation | P06493 (CDK1) | Uniprot |
K505 | Methylation | Uniprot | |
K509 | Methylation | Uniprot | |
K510 | Methylation | Uniprot | |
K569 | Ubiquitination | Uniprot | |
K597 | Ubiquitination | Uniprot | |
K602 | Ubiquitination | Uniprot | |
K629 | Ubiquitination | Uniprot | |
K634 | Ubiquitination | Uniprot | |
Y641 | Phosphorylation | O60674 (JAK2) | Uniprot |
S690 | Phosphorylation | Uniprot | |
Y696 | Phosphorylation | Uniprot | |
K713 | Ubiquitination | Uniprot | |
T718 | Phosphorylation | Uniprot | |
S729 | Phosphorylation | Uniprot | |
K735 | Methylation | Uniprot | |
K735 | Ubiquitination | Uniprot |
研究背景
Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2. Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.
Phosphorylated by AKT1. Phosphorylation by AKT1 reduces methyltransferase activity. Phosphorylation at Thr-345 by CDK1 and CDK2 promotes maintenance of H3K27me3 levels at EZH2-target loci, thus leading to epigenetic gene silencing.
Sumoylated.
Glycosylated: O-GlcNAcylation at Ser-75 by OGT increases stability of EZH2 and facilitates the formation of H3K27me3 by the PRC2/EED-EZH2 complex.
Nucleus.
Expressed in many tissues. Overexpressed in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma and testis.
Binds ATRX via the SET domain (Probable). Component of the PRC2/EED-EZH2 complex, which includes EED, EZH2, SUZ12, RBBP4 and RBBP7 and possibly AEBP2. The minimum components required for methyltransferase activity of the PRC2/EED-EZH2 complex are EED, EZH2 and SUZ12. The PRC2 complex may also interact with DNMT1, DNMT3A, DNMT3B and PHF1 via the EZH2 subunit and with SIRT1 via the SUZ12 subunit. Interacts with HDAC1 and HDAC2. Interacts with PRAME. Interacts with CDYL. Interacts with CLOCK, ARNTL/BMAL1 and CRY1 (By similarity). Interacts with DNMT3L; the interaction is direct (By similarity). Interacts with EZHIP; the interaction blocks EZH2 methyltransferase activity.
Belongs to the class V-like SAM-binding methyltransferase superfamily. Histone-lysine methyltransferase family. EZ subfamily.
研究领域
· Human Diseases > Cancers: Overview > MicroRNAs in cancer.
· Metabolism > Amino acid metabolism > Lysine degradation.
限制条款
产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。
产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。
Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。产品仅供科学研究使用。不用于诊断和治疗。
产品未经授权不得转售。
Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.